PolyPid Ltd. EBITDA 2011-2026 | PYPD

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA PolyPid Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-42 M	-25.3 M	-17.6 M	-18 M	-13.6 M	-10.1 M	-8.46 M	-	-3.51 M	-1.73 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-1.73 M	-42 M	-15.6 M

Quarterly EBITDA PolyPid Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-10.6 M	-	-	-	-7.27 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-7.27 M	-10.6 M	-8.95 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-679 M	$ 9.13	-0.76 %	$ 591 M	USA
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	1.19 M	$ 0.91	2.42 %	$ 6.69 M	China
Edesa Biotech EDSA	-6.83 M	$ 15.52	-2.39 %	$ 49.6 M	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	232 M	$ 22.47	1.19 %	$ 3.72 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Fortress Biotech FBIO	-69.8 M	$ 2.24	0.9 %	$ 62.5 M	USA
Galectin Therapeutics GALT	-20.1 M	$ 2.26	0.22 %	$ 144 M	USA
Galapagos NV GLPG	-166 M	$ 28.07	0.75 %	$ 2.69 B	Belgium
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Grifols, S.A. GRFS	595 M	$ 8.2	3.6 %	$ 6.83 B	Spain
Harmony Biosciences Holdings HRMY	232 M	$ 31.01	-0.13 %	$ 1.78 B	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
ImmuCell Corporation ICCC	4.43 M	$ 8.44	-	$ 76.2 M	USA
InflaRx N.V. IFRX	-37.3 M	$ 1.95	-1.77 %	$ 152 M	Germany
Immuron Limited IMRN	-2.87 M	$ 0.83	3.44 %	$ 6.55 M	Australia
Incyte Corporation INCY	1.61 B	$ 98.87	-0.23 %	$ 19.3 B	USA
InMed Pharmaceuticals INM	-7.75 M	$ 0.71	1.28 %	$ 1.74 M	Canada
INmune Bio INMB	-47.3 M	$ 1.35	1.5 %	$ 33.4 M	USA
Innoviva INVA	190 M	$ 23.13	0.35 %	$ 1.56 B	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Brainstorm Cell Therapeutics BCLI	-9.75 M	-	-2.5 %	$ 5.88 M	USA
BioNTech SE BNTX	15.3 B	$ 104.54	2.92 %	$ 27.2 B	Germany
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Jaguar Health JAGX	-44 M	$ 7.55	-4.13 %	$ 17.6 M	USA
KalVista Pharmaceuticals KALV	-111 M	$ 26.67	-0.02 %	$ 1.44 B	Britain
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Innate Pharma S.A. IPHA	-47.8 M	$ 1.43	-4.03 %	$ 235 M	France
Kamada Ltd. KMDA	-696 K	$ 8.15	0.49 %	$ 260 M	Israel
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	-190 M	-	-	$ 28.6 M	USA
Kazia Therapeutics Limited KZIA	-7.74 M	$ 13.24	6.56 %	$ 1.75 B	Australia
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Ligand Pharmaceuticals Incorporated LGND	12.6 M	$ 223.98	-0.39 %	$ 4.1 B	USA
Can-Fite BioPharma Ltd. CANF	-9.93 M	$ 3.22	7.69 %	$ 5.3 M	Israel
Liquidia Corporation LQDA	-49.8 M	$ 38.39	0.62 %	$ 3.3 B	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Aquestive Therapeutics AQST	-70.5 M	$ 4.08	0.74 %	$ 436 M	USA